EMEA (Europe, Middle East and Africa) Pulmonary Drugs Market Report 2017

October 2017 | 104 pages | ID: EEFF79EEAD9PEN
QYResearch

Abstracts

In this report, the EMEA Pulmonary Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Pulmonary Drugs for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Pulmonary Drugs market competition by top manufacturers/players, with Pulmonary Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• AstraZeneca plc
• Bayer AG'
• Teva Pharmaceutical Industries Ltd.'
• Actelion Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• GlaxoSmithKline plc
• Sunovion Pharmaceuticals, Inc.'

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

• Inhaled Corticosteroids (ICS)
• Long-Acting Beta2-Agonists (LABA)
• Antihistamine
• Vasodilators
• Short-Acting Beta2-Agonists (SABA)
• Anticholinergics
• Combination Drugs
• MAbs
• Enzymes
• Antibiotics & Antileukotrienes

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Pulmonary Drugs for each application, including

• Asthma & COPD
• Allergic Rhinitis
• Pulmonary Arterial Hypertension
• Cystic Fibrosis

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Pulmonary Drugs Market Report 2017

1 PULMONARY DRUGS OVERVIEW

1.1 Product Overview and Scope of Pulmonary Drugs
1.2 Classification of Pulmonary Drugs
  1.2.1 EMEA Pulmonary Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Pulmonary Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Inhaled Corticosteroids (ICS)
  1.2.4 Long-Acting Beta2-Agonists (LABA)
  1.2.5 Antihistamine
  1.2.6 Vasodilators
  1.2.7 Short-Acting Beta2-Agonists (SABA)
  1.2.8 Anticholinergics
  1.2.9 Combination Drugs
  1.2.10 MAbs
  1.2.11 Enzymes
  1.2.12 Antibiotics & Antileukotrienes
1.3 EMEA Pulmonary Drugs Market by Application/End Users
  1.3.1 EMEA Pulmonary Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Asthma & COPD
  1.3.3 Allergic Rhinitis
  1.3.4 Pulmonary Arterial Hypertension
  1.3.5 Cystic Fibrosis
1.4 EMEA Pulmonary Drugs Market by Region
  1.4.1 EMEA Pulmonary Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Pulmonary Drugs (2012-2022)
  1.5.1 EMEA Pulmonary Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Pulmonary Drugs Revenue and Growth Rate (2012-2022)

2 EMEA PULMONARY DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Pulmonary Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Pulmonary Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Pulmonary Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Pulmonary Drugs Sale Price by Players (2012-2017)
2.2 EMEA Pulmonary Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Pulmonary Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Pulmonary Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Pulmonary Drugs Sale Price by Type (2012-2017)
2.3 EMEA Pulmonary Drugs (Volume) by Application
2.4 EMEA Pulmonary Drugs (Volume and Value) by Region
  2.4.1 EMEA Pulmonary Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Pulmonary Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Pulmonary Drugs Sales Price by Region (2012-2017)

3 EUROPE PULMONARY DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Pulmonary Drugs Sales and Value (2012-2017)
  3.1.1 Europe Pulmonary Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Pulmonary Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Pulmonary Drugs Sales and Market Share by Type
3.3 Europe Pulmonary Drugs Sales and Market Share by Application
3.4 Europe Pulmonary Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Pulmonary Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Pulmonary Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Pulmonary Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Pulmonary Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Pulmonary Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Pulmonary Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Pulmonary Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Pulmonary Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST PULMONARY DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Pulmonary Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Pulmonary Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Pulmonary Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Pulmonary Drugs Sales and Market Share by Type
4.3 Middle East Pulmonary Drugs Sales and Market Share by Application
4.4 Middle East Pulmonary Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Pulmonary Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Pulmonary Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Pulmonary Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Pulmonary Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Pulmonary Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Pulmonary Drugs Sales and Growth Rate (2012-2017)

5 AFRICA PULMONARY DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Pulmonary Drugs Sales and Value (2012-2017)
  5.1.1 Africa Pulmonary Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Pulmonary Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Pulmonary Drugs Sales and Market Share by Type
5.3 Africa Pulmonary Drugs Sales and Market Share by Application
5.4 Africa Pulmonary Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Pulmonary Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Pulmonary Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Pulmonary Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Pulmonary Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Pulmonary Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Pulmonary Drugs Sales and Growth Rate (2012-2017)

6 EMEA PULMONARY DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 AstraZeneca plc
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Pulmonary Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 AstraZeneca plc Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Bayer AG?
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Pulmonary Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bayer AG? Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Teva Pharmaceutical Industries Ltd.?
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Pulmonary Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Actelion Pharmaceuticals, Inc.
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Pulmonary Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Boehringer Ingelheim GmbH
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Pulmonary Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Boehringer Ingelheim GmbH Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 F. Hoffmann-La Roche Ltd.
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Pulmonary Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Merck & Co., Inc.
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Pulmonary Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Merck & Co., Inc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Novartis AG
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Pulmonary Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Novartis AG Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 GlaxoSmithKline plc
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Pulmonary Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 GlaxoSmithKline plc Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Sunovion Pharmaceuticals, Inc.?
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Pulmonary Drugs Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 PULMONARY DRUGS MANUFACTURING COST ANALYSIS

7.1 Pulmonary Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Pulmonary Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Pulmonary Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Pulmonary Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA PULMONARY DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Pulmonary Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Pulmonary Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Pulmonary Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Pulmonary Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Pulmonary Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Pulmonary Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Pulmonary Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Pulmonary Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Pulmonary Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Pulmonary Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Pulmonary Drugs
Figure EMEA Pulmonary Drugs Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Pulmonary Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Inhaled Corticosteroids (ICS) Product Picture
Figure Long-Acting Beta2-Agonists (LABA) Product Picture
Figure Antihistamine Product Picture
Figure Vasodilators Product Picture
Figure Short-Acting Beta2-Agonists (SABA) Product Picture
Figure Anticholinergics Product Picture
Figure Combination Drugs Product Picture
Figure MAbs Product Picture
Figure Enzymes Product Picture
Figure Antibiotics & Antileukotrienes Product Picture
Figure EMEA Pulmonary Drugs Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Pulmonary Drugs by Application in 2016
Figure Asthma & COPD Examples
Figure Allergic Rhinitis Examples
Figure Pulmonary Arterial Hypertension Examples
Figure Cystic Fibrosis Examples
Figure EMEA Pulmonary Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Pulmonary Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Pulmonary Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Pulmonary Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Pulmonary Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Pulmonary Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Pulmonary Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Pulmonary Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Pulmonary Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Pulmonary Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Pulmonary Drugs Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Pulmonary Drugs Sales Share by Players (2012-2017)
Figure 2016 Pulmonary Drugs Sales Share by Players
Figure 2017 Pulmonary Drugs Sales Share by Players
Figure EMEA Pulmonary Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Pulmonary Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Pulmonary Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Pulmonary Drugs Revenue Share by Players
Table 2017 EMEA Pulmonary Drugs Revenue Share by Players
Table EMEA Pulmonary Drugs Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Pulmonary Drugs Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Pulmonary Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Pulmonary Drugs by Type (2012-2017)
Figure EMEA Pulmonary Drugs Sales Market Share by Type (2012-2017)
Table EMEA Pulmonary Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Pulmonary Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Pulmonary Drugs by Type in 2016
Table EMEA Pulmonary Drugs Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Pulmonary Drugs Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Pulmonary Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Pulmonary Drugs by Application (2012-2017)
Figure EMEA Pulmonary Drugs Sales Market Share by Application in 2016
Table EMEA Pulmonary Drugs Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Pulmonary Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Pulmonary Drugs by Region (2012-2017)
Figure EMEA Pulmonary Drugs Sales Market Share in 2016
Table EMEA Pulmonary Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Pulmonary Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Pulmonary Drugs by Region (2012-2017)
Figure EMEA Pulmonary Drugs Revenue Market Share Regions in 2016
Table EMEA Pulmonary Drugs Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Pulmonary Drugs Revenue and Growth Rate (2012-2017)
Table Europe Pulmonary Drugs Sales (K Units) by Type (2012-2017)
Table Europe Pulmonary Drugs Market Share by Type (2012-2017)
Figure Europe Pulmonary Drugs Market Share by Type in 2016
Table Europe Pulmonary Drugs Sales (K Units) by Application (2012-2017)
Table Europe Pulmonary Drugs Market Share by Application (2012-2017)
Figure Europe Pulmonary Drugs Market Share by Application in 2016
Table Europe Pulmonary Drugs Sales (K Units) by Countries (2012-2017)
Table Europe Pulmonary Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Pulmonary Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Pulmonary Drugs Sales Market Share by Countries in 2016
Table Europe Pulmonary Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Pulmonary Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Pulmonary Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Pulmonary Drugs Revenue Market Share by Countries in 2016
Figure Germany Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure France Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UK Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Pulmonary Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Pulmonary Drugs Sales (K Units) by Type (2012-2017)
Table Middle East Pulmonary Drugs Market Share by Type (2012-2017)
Figure Middle East Pulmonary Drugs Market Share by Type (2012-2017)
Table Middle East Pulmonary Drugs Sales (K Units) by Applications (2012-2017)
Table Middle East Pulmonary Drugs Market Share by Applications (2012-2017)
Figure Middle East Pulmonary Drugs Sales Market Share by Application in 2016
Table Middle East Pulmonary Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Pulmonary Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Pulmonary Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Pulmonary Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Pulmonary Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Pulmonary Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Pulmonary Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Pulmonary Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Pulmonary Drugs Sales (K Units) by Type (2012-2017)
Table Africa Pulmonary Drugs Sales Market Share by Type (2012-2017)
Figure Africa Pulmonary Drugs Sales Market Share by Type (2012-2017)
Figure Africa Pulmonary Drugs Sales Market Share by Type in 2016
Table Africa Pulmonary Drugs Sales (K Units) by Application (2012-2017)
Table Africa Pulmonary Drugs Sales Market Share by Application (2012-2017)
Figure Africa Pulmonary Drugs Sales Market Share by Application (2012-2017)
Table Africa Pulmonary Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Africa Pulmonary Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Pulmonary Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Pulmonary Drugs Sales Market Share by Countries in 2016
Table Africa Pulmonary Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Pulmonary Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Pulmonary Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Pulmonary Drugs Revenue Market Share by Countries in 2016
Figure South Africa Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Table AstraZeneca plc Pulmonary Drugs Basic Information List
Table AstraZeneca plc Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AstraZeneca plc Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure AstraZeneca plc Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure AstraZeneca plc Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table Bayer AG? Pulmonary Drugs Basic Information List
Table Bayer AG? Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bayer AG? Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Bayer AG? Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure Bayer AG? Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Basic Information List
Table Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure Teva Pharmaceutical Industries Ltd.? Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table Actelion Pharmaceuticals, Inc. Pulmonary Drugs Basic Information List
Table Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure Actelion Pharmaceuticals, Inc. Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table Boehringer Ingelheim GmbH Pulmonary Drugs Basic Information List
Table Boehringer Ingelheim GmbH Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure Boehringer Ingelheim GmbH Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table F. Hoffmann-La Roche Ltd. Pulmonary Drugs Basic Information List
Table F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure F. Hoffmann-La Roche Ltd. Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table Merck & Co., Inc. Pulmonary Drugs Basic Information List
Table Merck & Co., Inc. Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck & Co., Inc. Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Merck & Co., Inc. Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure Merck & Co., Inc. Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table Novartis AG Pulmonary Drugs Basic Information List
Table Novartis AG Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis AG Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Novartis AG Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure Novartis AG Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline plc Pulmonary Drugs Basic Information List
Table GlaxoSmithKline plc Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure GlaxoSmithKline plc Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure GlaxoSmithKline plc Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline plc Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Basic Information List
Table Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Sales Market Share in EMEA (2012-2017)
Figure Sunovion Pharmaceuticals, Inc.? Pulmonary Drugs Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pulmonary Drugs
Figure Manufacturing Process Analysis of Pulmonary Drugs
Figure Pulmonary Drugs Industrial Chain Analysis
Table Raw Materials Sources of Pulmonary Drugs Major Manufacturers in 2016
Table Major Buyers of Pulmonary Drugs
Table Distributors/Traders List
Figure EMEA Pulmonary Drugs Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Pulmonary Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Pulmonary Drugs Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Pulmonary Drugs Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Pulmonary Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Pulmonary Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Pulmonary Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Pulmonary Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Pulmonary Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Pulmonary Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Pulmonary Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Pulmonary Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Pulmonary Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Pulmonary Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Pulmonary Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Pulmonary Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Pulmonary Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Pulmonary Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Pulmonary Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Pulmonary Drugs Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Pulmonary Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Pulmonary Drugs Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Pulmonary Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources